After $2.2B Zantac settlement, GSK now faces investor lawsuit over the heartburn medication
With a $2.2 billion settlement, GSK has resolved most of its Zantac litigation. But now it faces a proposed class-action lawsuit for allegedly deceiving investors about its knowledge of a potential carcinogen in the heartburn medicine.
With a $2.2 billion settlement, GSK has resolved most of its Zantac litigation. But now it faces a proposed class-action lawsuit for allegedly deceiving investors about its knowledge of a potential carcinogen in the heartburn medicine.
